Knockdown of PARP-1 inhibits proliferation and ERK signals, increasing drug sensitivity in osteosarcoma U2OS cells

Oncology Research

Volumn 24, Issue 4, 2016, Pages 279-286

  Li, Sheng ^a   Cui, Zhengli ^a   Meng, Xianfeng ^a  

^a Department of Otolaryngology   (China)

Author keywords

Chemoresistance; Cisplatin; ERK1 2; Osteosarcoma; PARP 1

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 3;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; U2OS CELL LINE; BONE TUMOR; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOSARCOMA; POLY (ADP-RIBOSE) POLYMERASE-1; RNA, SMALL INTERFERING;

EID: 84981731015     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14666990347554     Document Type: Article

References (22)

1. Isakoff, M. S.; Bielack, S. S.; Meltzer, P.; Gorlick, R. Osteosarcoma: Current treatment and a collaborative pathway to success. J. Clin. Oncol. 33(27):3029-3035; 2015.
2. Aguilar-Quesada, R.; Munoz-Gamez, J. A.; Martin-Oliva, D.; Peralta-Leal, A.; Quiles-Perez, R.; Rodriguez-Vargas, J. M.; Ruiz de Almodovar, M.; Conde, C.; Ruiz-Extremera, A.; Oliver, F. J. Modulation of transcription by PARP-1: Consequences in carcinogenesis and inflammation. Curr. Med. Chem. 14(11):1179-1187; 2007.
3. Kraus, W. L.; Hottiger, M. O. PARP-1 and gene regulation: Progress and puzzles. Mol. Aspects Med. 34(6):1109-1123; 2013.
4. Langelier, M. F.; Pascal, J. M. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr. Opin. Struct. Biol. 23(1):134-143; 2013.
5. Vyas, S.; Chang, P. New PARP targets for cancer therapy. Nat. Rev. Cancer 14(7):502-509; 2014.
6. Li, Z.; Lv, T.; Liu, Y.; Huang, X.; Qiu, Z.; Li, J. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma. Cancer Biomark. 16(4):633-639; 2016.
7. Xu, X.; Liu, Z.; Wang, J.; Xie, H.; Li, J.; Cao, J.; Zhou, L.; Zheng, S. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma. Oncotarget 7(12):13730-13741; 2016.
8. Mazzotta, A.; Partipilo, G.; De Summa, S.; Giotta, F.; Simone, G.; Mangia, A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol. 37(5):6143-6153; 2016.
9. Simbulan-Rosenthal, C. M.; Rosenthal, D. S.; Iyer, S.; Boulares, H.; Smulson, M. E. Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Mol. Cell. Biochem. 193(1-2):137-148; 1999.
10. Zheng, Y. D.; Xu, X. Q.; Peng, F.; Yu, J. Z.; Wu, H. The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells. Oncol. Rep. 25(5):1399-1405; 2011.
11. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773(8):1263-1284; 2007.
12. Cohen-Armon, M. PARP-1 activation in the ERK signaling pathway. Trends Pharmacol. Sci. 28(11):556-560; 2007.
13. Si, H.; Peng, C.; Li, J.; Wang, X.; Zhai, L.; Li, X.; Li, J. RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro. Int. J. Oncol. 40(4):1291-1297; 2012.
14. Na, K. Y.; Kim, Y. W.; Park, Y. K. Mitogen-activated protein kinase pathway in osteosarcoma. Pathology 44(6):540-546; 2012.
15. Park, S. H.; Noh, S. J.; Kim, K. M.; Bae, J. S.; Kwon, K. S.; Jung, S. H.; Kim, J. R.; Lee, H.; Chung, M. J.; Moon, W. S.; et al. Expression of DNA damage response molecules PARP1, gammaH2AX, BRCA1, and BRCA2 predicts poor survival of breast carcinoma patients. Transl. Oncol. 8(4):239-249; 2015.
16. Barboro, P.; Ferrari, N.; Capaia, M.; Petretto, A.; Salvi, S.; Boccardo, S.; Balbi, C. Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression. Int. J. Cancer 137(7):1574-1586; 2015.
17. Li, L.; Chang, W.; Yang, G.; Ren, C.; Park, S.; Karantanos, T.; Karanika, S.; Wang, J.; Yin, J.; Shah, P. K. and others. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci. Signal. 7(326):ra47; 2014.
18. Yuan, K.; Sun, Y.; Zhou, T.; McDonald, J.; Chen, Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin. Cancer Res. 19(17):4750-4759; 2013.
19. Klauschen, F.; von Winterfeld, M.; Stenzinger, A.; Sinn, B. V.; Budczies, J.; Kamphues, C.; Bahra, M.; Wittschieber, D.; Weichert, W.; Striefler, J.; et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology 61(3):409-416; 2012.
20. Ganzinelli, M.; Mariani, P.; Cattaneo, D.; Fossati, R.; Fruscio, R.; Corso, S.; Ricci, F.; Broggini, M.; Damia, G. Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations. Eur. J. Cancer 47(7):1086-1094; 2011.
21. Park, S. H.; Jang, K. Y.; Kim, M. J.; Yoon, S.; Jo, Y.; Kwon, S. M.; Kim, K. M.; Kwon, K. S.; Kim, C. Y.; Woo, H. G. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget 6(42):44819-44831; 2015.
22. Wang, L.; Cai, W.; Zhang, W.; Chen, X.; Dong, W.; Tang, D.; Zhang, Y.; Ji, C.; Zhang, M. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene. Oncotarget 6(29):27490-27504; 2015.